Abstract: The present invention relates to an apparatus for the extracorporeal removal of protein-bound toxins from blood comprising at least one blood purification apparatus, in particular at least one dialysis machine, hemofilter or adsorber, as well as at least one means for generating a field in the blood purification apparatus and/or in an element in flow communication with the blood purification apparatus, in particular in a line section connected to the blood purification apparatus, wherein the means comprises at least two strip conductors which are arranged on at least two preferably oppositely disposed sides of the blood purification apparatus or of the element such that the field is preferably predominantly generated within the blood purification apparatus or preferably predominantly within the element.

Abstract: The present invention relates to pharmaceutical compositions containing steviol glycoside and or steviol glycoside derivatives as well as to their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis.

Abstract: The invention relates to the field of diagnosis of epithelial-to-mesenchymal transition (EMT), such as mesothelial-to-mesenchymal transition (MMT), in particular EMT of the peritoneum, which often occurs upon peritoneal dialysis. The invention provides a method and kit based on markers comprising at least one extracellular matrix protein, e.g., collagen 13, collagen 6, and/or keratin 34, at least one protein involved in building and/or restructuring of extracellular matrix, e.g., matrix metalloproteinase 1, at least one protein involved in cell-cell and/or cell-matrix contacts, e.g., cadherin 13 or thrombospondin 1, at least one growth factor, e.g., VEGF, and, optionally, at least one BMP antagonist, e.g., Gremlin 1.

Abstract: The present invention relates to pharmaceutical compositions containing steviol glycoside and or steviol glycoside derivatives as well as to their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis.

Abstract: The present invention relates to magnesium-liposome complexes with a delayed release of magnesium, coated at least partially with a polyalkylene glycol compound. In addition, the present invention relates to methods for synthesis of the magnesium-liposome complexes as well as use thereof in the treatment of diseases associated with a magnesium deficiency.

Abstract: The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.

Abstract: The invention provides CTGF which is associated with the cardiovascular diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases and hematological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CTGF as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides PRSS23, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRSS23 as well as pharmaceutical compositions comprising such compounds. The invention also provides PRSS23 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.

Abstract: The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.